Diabetes

Sales & Marketing

Unpacking EASD 2024: Key themes, topics, and influencers

This September, Madrid played host to the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD).

News

Disparate global Wegovy prices listed at congressional hearing

Novo Nordisk CEO reticent on lowering semaglutide prices

Novo Nordisk chief executive Lars Fruergaard Jørgensen was taken to task by US lawmakers over the price of the company's semaglutide drugs for diabetes and obesity at a congressional hearin

News

Study reignites debate on GLP-1 drugs and suicide risk

A study has found a higher risk of suicidal thoughts in users of Novo Nordisk's GLP-1 agonist-based drugs for diabetes and obesity, even though regulators in the US and EU concluded there w

News

Lilly says tirzepatide staves off diabetes in phase 3 trial

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and ob

News

Lilly says tirzepatide supply issues are resolving

Eli Lilly has raised its revenue guidance for 2024 by $3 billion, after reporting strong growth for tirzepatide in diabetes and obesity, fuelled by the end of supply constraints for startin

News

Patients resist Novo Nordisk plan to stop making Levemir

A patient advocacy group has started a campaign to stop Novo Nordisk from following through on a plan to stop making insulin product Levemir, arguing that it could leave some diabetics with

Unpacking EASD 2024: Key themes, topics, and influencers

Novo Nordisk CEO reticent on lowering semaglutide prices

Study reignites debate on GLP-1 drugs and suicide risk

Lilly says tirzepatide staves off diabetes in phase 3 trial

Lilly says tirzepatide supply issues are resolving

Patients resist Novo Nordisk plan to stop making Levemir

Infex chases after Insmed with bronchiectasis trial win

Discover a new era of healthcare panel engagement: Grounded ...

Diabetes

Editor's Picks